Loading stock data…
$7.28-0.24 (-3.13%)
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
Evolus, Inc. in the Healthcare sector is trading at $7.28 with a market capitalization of $481M. Wall Street consensus targets $15.00 (5 analysts), implying a +106.2% move over the next 12 months. The stock is currently 22% below its 52-week high of $9.31, remaining 17.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $84.08M↑ | $73.14M↓ | $90.30M↑ | $68.97M↓ | $69.39M |
| Gross Profit | $57.18M↑ | $48.90M↓ | $59.29M↑ | $45.84M↑ | $45.32M |
| Operating Income | -$3.29M↑ | -$6.86M↓ | -$291,000↑ | -$10.16M↑ | -$14.12M |
| Net Income | -$8.05M↑ | -$10.67M↓ | $130,000↑ | -$15.74M↑ | -$17.14M |
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the te...